King of Prussia’s biotherapeutics company CSL Behring is acquiring Calimmune, a clinical-stage biotechnology company, for $91 million, writes Linda Loyd for Philly.com.

But the end cost may be higher, as the deal also includes milestone payments based on performance of up to $325 million. With the acquisition, the Montgomery County company will expand its product pipeline to include an early-stage stem-cell gene therapy for sickle-cell disease.

Calimmune is currently working on a gene therapy using its two “platform” technologies. These address the challenges that can occur in the manufacturing and administration of gene and stem-cell-based treatments.

According to CSL Behring, “Select+” and “Cytegrity” technologies are “designed to address some of the major challenges currently associated with the commercialization of stem-cell therapy.”

[uam_ad id=”54865″]

Among the issues addressed by the two technologies, is the ability to consistently produce high-quality products while improving their engraftment, efficacy, and tolerability.

“Calimmune shares in our promise and focus to improve the lives of patients with rare and serious medical conditions,” said Paul Perreault, CSL’s CEO and managing partner. “The acquisition represents another important step in the execution of our strategy for sustainable growth.”

The deal is expected to be finalized in mid-September.

Read more about CSL Behring’s acquisition at Philly.com by clicking here.

[uam_ad id=”55912″]